Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is an American biopharmaceutical company founded in 1988 by Leonard Schleifer (current CEO) and George Yancopoulos (current Chief Scientific Officer) and headquartered in Tarrytown, New York. Regeneron is one of the most successful mid-cap-to-large-cap biotechs in the industry, with a portfolio of approved biologics including Eylea (aflibercept, for wet age-related macular degeneration — Regeneron's flagship product), Dupixent (dupilumab, partnered with Sanofi for atopic dermatitis and other Type 2 inflammatory diseases), Libtayo (cemiplimab, partnered with Sanofi for cutaneous squamous cell carcinoma), and Praluent (alirocumab, partnered with Sanofi for LDL cholesterol reduction). Regeneron's pipeline includes multiple bispecific antibodies (linvoseltamab for multiple myeloma, odronextamab for B-cell lymphomas) and the antibodycocktail REGN-COV (casirivimab/imdevimab for COVID-19, now largely superseded by newer variants). The company has committed $7B+ in manufacturing investments across its New York and North Carolina facilities, with a $2B investment in a new Saratoga Springs, NY manufacturing plant announced in 2025 and selected for the FDA PreCheck Pilot Program in June 2026.